RNAi Therapy for Glaucoma via Tight Junction Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly primary open-angle glaucoma, are inadequate in reducing intraocular pressure (IOP) for a significant proportion of patients, leading to elevated IOP and potential blindness, with existing medications and surgical interventions being costly and not effective for all cases.
Innovation Solution
An RNAi-inducing agent is used to target and inhibit the expression of tight junction proteins in Schlemm's canal endothelial cells, specifically claudin-11, Tricellulin, and ZO-1, to increase paracellular permeability and reduce outflow resistance, thereby lowering IOP.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional medications are used to reduce intraocular pressure, then IOP is lowered in some patients, but treatment is ineffective for a significant proportion of patients and costs are high
Solution Approach 1:
The invention changes the therapeutic parameter from pharmacological modulation of aqueous humor production or unconventional outflow to direct modulation of tight junction protein expression in Schlemm's canal endothelial cells. This parameter change targets the underlying pathophysiology of reduced paracellular permeability, providing a more reliable and universally effective treatment mechanism that addresses the root cause rather than symptomatic management.
Solution Approach 2:
The invention replaces the mechanical/pharmacological approach of conventional medications with a molecular biology-based RNA interference mechanism. Instead of using drugs that attempt to modify fluid dynamics or prostaglandin pathways, the invention uses siRNA to specifically degrade mRNA encoding tight junction proteins, thereby directly increasing paracellular permeability through a targeted molecular mechanism that bypasses the limitations of conventional pharmacotherapy.
2Reliability
If invasive surgical interventions are performed to lower IOP, then IOP reduction is achieved, but the procedure becomes more complex and carries higher risks
Solution Approach 1:
The invention introduces RNA interference molecules (siRNA) as an intermediary therapeutic agent that mediates the effect between administration and physiological outcome. Instead of directly performing surgical manipulation of trabecular meshwork or Schlemm's canal, the siRNA acts as an intermediary that delivers the therapeutic effect by modulating protein expression, thereby achieving IOP reduction without the complexity and risks of invasive surgery.
Solution Approach 2:
The invention replaces mechanical surgical interventions with a molecular-level mechanism. Instead of physically altering eye structures through surgery, the treatment uses RNA interference to modulate gene expression and increase paracellular permeability, substituting a complex mechanical procedure with a simpler molecular therapy that achieves the same therapeutic goal with reduced complexity and risk.
3Reliability
If tight junction proteins are inhibited to increase outflow facility, then IOP is reduced, but the mechanism of action is novel and requires validation
Solution Approach 1:
The invention implements a feedback mechanism where RNA interference molecules specifically target and degrade mRNA encoding tight junction proteins (claudin-11, Tricellulin, ZO-1), leading to reduced protein expression and increased paracellular permeability. This feedback loop allows for precise control of the therapeutic effect by directly linking the presence of siRNA to the downregulation of specific proteins, thereby achieving reliable IOP reduction through a well-defined molecular mechanism that can be measured and validated at multiple levels (mRNA, protein, and functional permeability).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces IOP by increasing outflow facility and creating intercellular gaps in the inner wall of Schlemm's canal endothelial cells, providing a novel approach for glaucoma treatment that complements existing therapies and addresses medication resistance.
Implementation Method 1
An RNAi-inducing agent is used to target and inhibit the expression of tight junction proteins in Schlemm's canal endothelial cells, specifically claudin-11, Tricellulin, and ZO-1
Data Source
AI summary
The present invention is directed to an RNAi-inducing agent capable of reducing and/or inhibiting the expression of proteins associated with the tight junction complex joining Schlemm's canal endothelial cells (SCEC) in the eye of a subject for use in the prevention and/or treatment of glaucoma. Specifically, the RNAi-inducing agent is capable of reducing and/or inhibiting the expression of proteins expressed in the tight junction complex or supporting the tight junction complex joining Schlemm's canal endothelial cells (SCEC) in the eye of a subject for use in the prevention and/or treatment of glaucoma. Methods using this RNAi-inducing agent are also contemplated.